Is insulin resistance atherogenic? Possible mechanisms

Atherosclerosis Supplements

Volumn 7, Issue 4, 2006, Pages 11-15

  DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Atherosclerosis; Diabetes; Hyperglycaemia; Insulin; Insulin resistance

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; SULFONYLUREA;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; INSULIN; INSULIN RESISTANCE; OBESITY; RISK FACTORS;

EID: 33746218171     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2006.05.002     Document Type: Article

References (38)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
3. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 321 (2000) 405-412
4. Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
5. Rubins H.B., Robins S.J., Collins D., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med 341 (1999) 410-418
6. Kannel WB. Status of risk factors and their consideration in antihypertensive therapy. Am J Cardiol 59 (1987) 80A-90A
7. Lamarche B., St-Pierre A.C., Ruel I.L., Cantin B., Dagenais G.R., and Despres J.P. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol 17 (2001) 859-865
8. Yip J., Facchini F.S., and Reaven G.M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83 (1998) 2773-2776
9. Bays H., Mandarino L., and DeFronzo R.A. Role of the adipocytes, FFA, and ectopic fat in the pathogenesis of type 2 diabetes mellitus: PPAR agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89 (2004) 463-478
10. Mokdad A.H., Ford E.S., Bowman B.A., et al. Diabetes trends in the US: 1990-1998. Diabetes Care 23 (2000) 1278-1283
11. Groop L.C., Bonadonna R.C., Del Prato S., Ratheiser K., Zyck K., and DeFronzo R.A. Effect of insulin on oxidative and non-oxidative pathways of glucose and FFA metabolism in NIDDM. Evidence for multiple sites of insulin resistance. J Clin Invest 84 (1989) 205-213
12. Groop L., Saloranta C., Shank M., Bonadonna R.C., Ferrannini E., and DeFronzo R.A. The role of free fatty acid metabolism in the pathogensis of insulin resistance in obesity and non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 72 (1991) 96-107
13. DeFronzo R.A. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5 (1997) 177-269
14. Taskinen M.R. Lipoprotein lipase in diabetes. Diabetes Metab Rev 3 (1987) 551-570
15. De Vriese A.S., Verbeuren T.J., Van de Voorde J., Lameire N.H., and Vanhoutte P.M. Endothelial dysfunction in diabetes. Brit J Pharmacol 130 (2000) 963-974
16. Caballero A.E., Arora S., Saouaf R., et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48 (1999) 1856-1862
17. Natali A., Baldeweg S., Toschi E., et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 27 (2004) 1349-1357
18. Jaap A.J., Shorc A.C., and Tooke J.E. Relationship of insulin resistance to microvascular dysfunction in subjects with fasting hyperglycemia. Diabetologia 40 (1997) 238-243
19. Baron AD. Hemodynamic actions of insulin. Am J Physiol 367 (1994) E187-E202
20. Gulli G., Ferrannini E., Stern M., Haffner S., and DeFronzo R.A. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 41 (1992) 1575-1586
21. Henry R.R., Gumbiner B., Ditzler T., Wallace P., Lyon R., and Glauber H.S. Intensive conventional insulin therapyfor type 2 diabetes. Metabolic effects during a 5 months outpatient trial. Diabetes Care 16 (1993) 21-31
22. DeFronzo R.A., and Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and ASCVD. Diabetes Care-Rev 14 (1991) 173-194
23. Stout R.W. The effect of insulin on the incorporation of (1-C) sodium acetate into the lipids of the rat aorta. Diabetologia 7 (1971) 367-372
24. Duff G.L., and McMillan G.C. The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit. J Exp Med 89 (1949) 611-630
25. Stamler J., Pick R., and Katz L.N. Effect of insulin in the induction and regression of atherosclerosis in the chick. Circ Res 8 (1960) 572-576
26. Bressler P., Bailey S., Matsuda M., and DeFronzo R.A. Insulin resistance and coronary artery disease. Diabetologia 39 (1996) 1345-1350
27. Reaven G. Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease. Circulation 106 (2002) 286-288
28. Haffner S.M., D'Agostino R., Mykkanen L., et al. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors. The Insulin Resistance Atherosclerosis Study. Diabetes Care 22 (1999) 562-568
29. Kendall D.M., Sobel B.E., Coulston A.M., et al. The insulin resistance syndrome and coronary artery disease. Coronary Artery Dis 14 (2003) 335-340
30. Golden S.H., Folsom A.R., Coresh J., et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis. Diabetes 51 (2002) 3069-3076
31. Cusi K., Maezono K., Osman A., et al. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle. J Clin Invest 105 (2000) 311-320
32. Wang C.C., Goalstone M.L., and Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 53 (2004) 2735-2740
33. Bajaj M., and DeFronzo R.A. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol 10 (2003) 311-323
34. Hsueh W.A., and Law R.E. Insulin signaling in the arterial wall. Am J Cardiol 84 (1999) 21J-24J
35. Miyazaki Y., He H., Mandarino L.J., and DeFronzo R.A. Rosiglitazone improves downstream insulin-receptor signaling in type 2 diabetic patients. Diabetes 52 (2003) 1943-1950
36. Yki-Jarvinen H. Thiazolidinediones. New Engl J Med 351 (2004) 1106-1118
37. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366 (2005) 1279-1289
38. Gastaldelli A., Ferrannini E., Miyazaki Y., Matsuda M., and DeFronzo R.A. Beta cell dysfunction and glucose intolerance: Results from the San Antonio Metabolism (SAM) Study. Diabetologia 47 (2004) 31-39